IGC Pharma, Inc. (IGC)
(Delayed Data from AMEX)
$0.34 USD
-0.01 (-1.49%)
Updated Aug 6, 2025 10:34 AM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IGC 0.34 -0.01(-1.49%)
Will IGC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IGC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGC
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
IGC: What are Zacks experts saying now?
Zacks Private Portfolio Services
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock
Other News for IGC
IGC Unveils Promising Preclinical Data for Alzheimer's Molecule IGC-M3
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of ...
IGC Pharma announces preclinical data on IGC-M3
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
IGC Showcases AI Innovations at 2025 Alzheimer's Conference | IGC Stock News